Overview
Coriolis Pharma, headquartered in Martinsried, Germany, is a globally recognized contract research and development organization (CRDO) that specializes in the formulation development of biopharmaceuticals, including proteins, peptides, and vaccines. As a leader in drug product development and bioanalytical services, Coriolis Pharma provides a comprehensive range of services that includes formulation research, analytical services, forced degradation and stability testing, lyophilization, and the supply of pre-clinical material. With over 16 years of industry experience, Coriolis Pharma has supported over 930 different drug substances across various therapeutic modalities. The company has a robust track record, evidenced by the development of 145 formulations and successful management of over 2700 projects.
Leadership
Key Executives
- Silvia Steyrer-Gruber, Chief Executive Officer: Spearheads operational leadership and strategic growth, leveraging her extensive background in the pharmaceutical sector.
- Dr. Andrea Hawe, Chief Scientific Officer: Renowned for drug product development expertise, ensuring scientific rigor in operations.
- Dr. Tim Menzen, Chief Technology Officer: Recognized for contributions to pharmaceutical sciences, noted for his early career achievements.
- Johannes Clemens, Chief Commercial Officer: Drives global business development strategies to expand market presence.
- Dr. Frank Schaubhut, Chief Operating Officer: Focuses on operational efficiency with extensive pharmaceutical experience.
- Dr. Gerhard Sax, Chief of Staff: Overseeing program management, benefits from a solid academic and industrial background.
- André Steingröver, Chief Financial Officer: Directs financial strategies, supported by substantial healthcare economics expertise.
Board of Directors
- Peter Sölkner: Recent board member, playing a vital role in supporting corporate growth ambitions.
- Dr. Michael Wiggenhorn: Founder and strategic leader, guiding company initiatives.
Services and Achievements
Coriolis Pharma offers integrative services across the drug development lifecycle:
- Drug Product Development: Utilizing advanced formulation technologies to enhance drug stability and effectiveness.
- Analytical Services: Providing detailed quality and compliance analysis.
- Manufacturing Services: Specializing in liquid and lyophilized drug products powered by robust technologies.
Coriolis Pharma has an extensive global client base of 800 entities, spanning preclinical to commercial stages with an estimated annual revenue of $44.4 million and a workforce of 221 employees. The company achieved a 7% growth in its employee count over the previous year.
Recent Developments
Coriolis Pharma has recently expanded its global footprint by establishing a new entity in the U.S. to enhance its service offerings in the monoclonal antibodies domain. Additionally, the company's commitment to scientific innovation is reflected in over 160 peer-reviewed publications, such as research on "The Role of Asymmetric Flow Field-Flow Fractionation."
Recent Appointments
Aligned with their growth strategy, Coriolis Pharma recently appointed Johannes Clemens as the new Head of Business Development and Peter Sölkner to its Board of Directors.
Contact Information
Address:
Coriolis Pharma Research GmbH
Fraunhoferstraße 18 b
82152 Martinsried, Germany
Phone: +49 89 41 77 60 – 0
Further inquiries can be directed through their [website](https://www.coriolis-pharma.com/).
Competitive Landscape
Coriolis Pharma operates within a competitive environment with several key players:
Competitors by Industry and Revenue:
1. Nuvisan Pharma Services
- Revenue: $89.4 million
- Employees: 445
- Growth Rate: 9%
2. Hermes Arzneimittel GmbH
- Revenue: $17.7 million
- Employees: 88
- Growth Rate: 7%
3. Clariness
- Revenue: $32.4 million
- Employees: 161
- Growth Rate: 25%
4. Immatics Biotechnologies
- Revenue: $120.2 million
- Employees: 427
- Growth Rate: 17%
5. ITM Isotopen Technologien München
- Revenue: $49.6 million
- Employees: 247
- Growth Rate: 52%
Additional competitors include KBI Biopharma, Boehringer Ingelheim, Aldevron, and Siegfried, each notable for their unique capabilities in pharmaceutical and biopharmaceutical research and production.
Strategic Insights
Despite its smaller scale compared to some competitors, Coriolis Pharma maintains competitive strength through high-quality service delivery and innovation. The company’s strategic location in the biotech hub of Germany and its efficient operations, with a revenue per employee approximation of $201,000, support its robust position. Potential collaboration opportunities could further enhance its geography and service reach.
